



# Corporate Overview

February 28, 2024

ADVANCING IMMUNO-ONCOLOGY

# Forward-Looking Statements

Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the risks related to our ability to successfully commercialize our products, including AMTAGVI, for which we obtain U.S. Food and Drug Administration (“FDA”), European Medicines Agency (“EMA”), or other regulatory authority approval; the risk that the EMA or other regulatory authorities may not approve or may delay approval for our biologics license application (“BLA”) submission for lifileucel in metastatic melanoma; the acceptance by the market of our products, including AMTAGVI, and their potential pricing and/or reimbursement by payors, if approved (in the case of our product candidates), in the U.S. and other international markets and whether such acceptance is sufficient to support continued commercialization or development of our products, including AMTAGVI, or product candidates, respectively; our ability or inability to manufacture our therapies using third party manufacturers or at our own facility may adversely affect our commercial launch; the results of clinical trials with collaborators using different manufacturing processes may not be reflected in our sponsored trials; the risk regarding the successful integration of the recent Proleukin acquisition; the risk that the successful development or commercialization of our products, including AMTAGVI, may not generate sufficient revenue from product sales, and we may not become profitable in the near term, or at all; the risk that future competitive or other market factors may adversely affect the commercial potential for AMTAGVI; the risks related to the timing of and our ability to successfully develop, submit, obtain, or maintain FDA, EMA, or other regulatory authority approval of, or other action with respect to, our product candidates; whether clinical trial results from our pivotal studies and cohorts, and meetings with the FDA, EMA, or other regulatory authorities may support registrational studies and subsequent approvals by the FDA, EMA, or other regulatory authorities, including the risk that the planned single arm Phase 2 IOV-LUN-202 trial may not support registration; preliminary and interim clinical results, which may include efficacy and safety results, from ongoing clinical trials or cohorts may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials or in other prior trials or cohorts; the risk that enrollment may need to be adjusted for our trials and cohorts within those trials based on FDA and other regulatory agency input; the risk that the changing landscape of care for cervical cancer patients may impact our clinical trials in this indication; the risk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from the FDA, EMA, or other regulatory authorities; the risk that our interpretation of the results of our clinical trials or communications with the FDA, EMA, or other regulatory authorities may differ from the interpretation of such results or communications by such regulatory authorities (including from our prior meetings with the FDA regarding our non-small cell lung cancer clinical trials); the risk that clinical data from ongoing clinical trials of AMTAGVI will not continue or be repeated in ongoing or planned clinical trials or may not support regulatory approval or renewal of authorization; the risk that unanticipated expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements; the effects of the COVID-19 pandemic; and other factors, including general economic conditions and regulatory developments, not within our control.

# Global Leadership in Innovating, Developing and Delivering TIL Therapy for Patients with Cancer

## Platform

**700+**

Clinical Trial Patients  
Treated with Iovance TIL Products

**2**

Manufacturing Sites FDA Approved  
for Commercial Production

**22-day**

Proprietary Manufacturing Process

## Portfolio

**2**

Commercial Products

**AMTAGVI**  
(lifileucel)

**PROLEUKIN**  
(aldesleukin)

**7**

Active Clinical Trials

**5**

Tumor Types in Clinic

**3**

Fast  
Track

**1**

BTD

**1**

RMAT

Designations

## People & Assets

**~\$485M**

Cash Position as of 2/22/24<sup>1</sup>

**60+**

US and International Patents

**500+**

Employees

## Partners & Collaborators



The University of Texas  
MD Anderson  
Cancer Center



Yale  
CANCER  
CENTER



1. Unaudited cash position which includes net proceeds of approximately \$197.1 million from a follow-on equity financing in February of 2024.  
Abbreviations: BTD=Breakthrough Therapy Designation; FDA=U.S. Food and Drug Administration; RMAT=Regenerative Medicine Advanced Therapy Designation

# Iovance Solid Tumor Portfolio Highlights



**AMTAGVI<sup>™</sup>**  
(lifileucel) Suspension for IV infusion

*Post-anti-PD-1 advanced melanoma*  
**NOW APPROVED**



**PROLEUKIN<sup>®</sup>**  
(aldesleukin) Recombinant IL-2

*AMTAGVI treatment regimen*  
Advanced melanoma, renal cell carcinoma


	CANDIDATE	INDICATIONS	PHASE 1	PHASE 2	PHASE 3
Registration-Directed	Lifileucel + pembro	Frontline advanced melanoma	TILVANCE-301 Phase 3		Confirmatory, FTD
	LN-145	2L post-chemo & post-anti-PD-1 advanced NSCLC	IOV-LUN-202: Cohorts 1&2		
	Lifileucel	Post-chemo & post-anti-PD-1 cervical	C-145-04: Cohort 2	BTD, ODD	
Additional Pipeline	LN-145 + pembro	1L chemo and anti-PD-1 naïve cervical	C-145-04: Cohort 3*		
	Lifileucel	2L post-chemo & post-anti-PD-1 endometrial	Planned Phase 2		
	LN-145, LN-145 + ICI	2-4L incl. post-anti-PD-1 advanced NSCLC	IOV-COM-202: Cohorts 3A, 3B*,3C		
	LN-145 + ICI	1L advanced melanoma	IOV-COM-202: Cohort 1A		
Next Generation	PD-1 Inactivated TIL (IOV-4001)	Post anti-PD1 advanced melanoma	IOV-GM1-201: Cohort 1		
	PD-1 Inactivated TIL (IOV-4001)	2-4L incl. post-anti-PD-1 advanced NSCLC	IOV-GM1-201: Cohort 2		
	LN-145 Gen 3 + core biopsy	2L post-chemo & post-anti-PD-1 advanced NSCLC	IOV-LUN-202: Cohort 3		

\*Enrollment complete  
Abbreviations: 1L=first line; 2L=second line; 4L=fourth line; BTD=Breakthrough Therapy Designation; FTD=Fast Track Designation; ipi/nivo=ipilimumab/nivolumab; NSCLC=non-small cell lung cancer; ODD=Orphan Drug Designation; PD-1=programmed cell death protein-1; RMA=Regenerative Medicines Advanced Therapy; TIL=tumor infiltrating lymphocytes

# Tumor Infiltrating Lymphocytes (TIL): Leading Cell Therapy Platform for Solid Tumors


## TIL – Unique Proposed Mechanism of Action

- Individualized
- One-time therapy
- Deploys the patient's own T cells to fight cancer





**AMTAGVI™ (lifileucel):**  
**First and only one-time, individualized T cell therapy**  
**approved by FDA for a solid tumor cancer**



Actor portrayal and not a real image of a T cell.

**NOW APPROVED**

**AMTAGVI™**  
(lifileucel) Suspension  
for IV infusion

## ***The first and only FDA-approved T cell therapy for previously treated advanced (unresectable or metastatic) melanoma<sup>1</sup>***

*AMTAGVI™ is a one-time treatment unique for each patient.<sup>1</sup>*

### **Indication**

AMTAGVI (lifileucel) is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor.

This indication is approved under accelerated approval based on objective response rate (ORR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

### **Important Safety Information**

**WARNING: TREATMENT-RELATED MORTALITY, PROLONGED SEVERE CYTOPENIA, SEVERE INFECTION, CARDIOPULMONARY and RENAL IMPAIRMENT**

- Monitor patients for prolonged severe cytopenia and monitor for internal organ hemorrhage
- Administer filgrastim or a biosimilar product to patients beginning Day 1 after AMTAGVI and continuing daily until the absolute neutrophil count (ANC) is greater than 1000 per mm<sup>3</sup> for 3 consecutive days, or per institutional standard
- Treat severe infections
- Monitor cardiopulmonary and renal functions throughout the treatment course

Administer in an inpatient hospital setting. An intensive care facility and specialists skilled in cardiopulmonary or intensive care medicine must be available.

1. AMTAGVI USPI

# U.S. Unmet Medical Need for Metastatic Melanoma Therapy

AMTAGVI is the First FDA Approved Treatment Option After Progression on ICI (Anti-PD-1) Therapy and BRAF/MEK inhibitors

**15k**


Annual new cases  
of advanced  
melanoma in U.S.<sup>1</sup>

**8k**

Annual deaths  
in U.S.<sup>2</sup>

## Melanoma Drug-Treated Population in 2021

Unresectable / Metastatic (US)<sup>3</sup>



**High unmet need for patients  
who progress after immune  
checkpoint inhibitors**

More than half of patients  
progress **within 12 months**  
on current **1L ICIs**,  
regardless of BRAF  
mutation status<sup>4</sup>

1. Estimate of US incidence (2021) of unresectable or metastatic melanoma based on secondary and primary market research

2. National Cancer Institute Surveillance, Epidemiology and End Results (SEER) Program. 2023 Estimates. <https://seer.cancer.gov> accessed February 2024

3. Clarivate DRG Disease Landscape (2021)

4. Larkin et al, NEJM 2019; Robert et al, Lancet Oncology 2019; Tawbi et al, NEJM 2022

Abbreviations: 1L=first line therapy, 2L=second line therapy, 3L=third line therapy, 4L=fourth line therapy; ICI=immune checkpoint inhibitor; PD-1=programmed cell death protein-1



# AMTAGVI™ Delivered Deep and Durable Responses

## Cohort 4 Pivotal<sup>1</sup> (N=73)

**ORR 31.5%**

(95% CI: 21.1, 43.4)

**mDOR Not Reached**

**18.6 months follow up**

(Range: 1.4+, 26.3+; 95% CI: 4.1, NR)

## Supportive Pooled Data<sup>1</sup> (n=153)

**ORR 31.4%**

(95% CI: 24.1, 39.4)

**mDOR Not Reached**

**21.5 months follow up<sup>2</sup>**


(Range: 1.4+, 45.0+)

1. AMTAGVI USPI

2. Data on file.

CI, confidence interval; mDOR, median duration of response; NR, not reached.

# AMTAGVI™ C-144-01 4-year Follow Up



**21.9% of patients were alive at 4-year follow-up**

**ORR 31.4%**  
(95% CI: 24.1, 39.4)

**Not Reached**  
**mDOR**  
(95% CI: 8.3, NR)

48.1 months follow-up

# AMTAGVI™ Patient Journey

## AMTAGVI Autologous T Cell Therapy

### Treatment Decision & Reimbursement Approval




### Scheduling & Tumor Tissue Procurement




AMTAGVI starts with a piece of the patient's tumor tissue

### T Cell Therapy Manufacturing & Release Testing



TIL cells are grown into the billions in a manufacturing facility

### Treatment Regimen & Monitoring



- Lymphodepletion
- **AMTAGVI™ (lifileucel)**
- Short-Course Proleukin®

# Iovance Cell Therapy Center: iCTC

- Built-to-suit custom facility in Navy Yard Philadelphia
- Annual capacity for up to several thousand patients as built
- Expansion underway for additional capacity within iCTC over next few years
- Additional CDMO capacity
- Control to optimize capacity, quality & COGS

**FDA-Approved Cell Therapy Manufacturing Facility  
Dedicated to Commercial and Clinical TIL Cell Therapies**



**IOVANCE**  
BIOTHERAPEUTICS  
CELL THERAPY CENTER

**FOYA** 2022  
ISPE Facility of the Year Awards  
CATEGORY WINNER  
Honorable Mention



# Iovance Cell Therapy Center (iCTC): Capacity Expansion Plans

**Pre-Approval  
(Complete)**

**100s**

of patients/year

**Launch Prep**

in core suites for  
commercial

**4**

separate flex suites  
for clinical

**Today  
(as built)**

up to **2,000+**  
patients/year<sup>1</sup>

**12**

core suites for  
commercial

**4**

separate flex suites  
for clinical

**Site Expansion  
(in progress)<sup>2</sup>**

**5,000+**  
patients/year

**24**

core suites for  
commercial

**4**

separate flex suites  
for clinical

**iCTC +  
Future Site(s)**

**10,000+**  
patients/year

**iCTC**

**Adjacent and  
new sites<sup>3</sup>**

**Automation**

1. Ongoing staffing 2. Expansion within existing shell 3. Option to build on adjacent parcel

# Proleukin® (aldesleukin) Strategic Benefits

Global Rights Acquired in May of 2023

- Significant revenue anticipated with AMTAGVI™ launch
- IL-2 supply chain secured for AMTAGVI regimen
- Lower clinical trial costs and COGS anticipated



**Short course Proleukin® is administered after AMTAGVI® to promote T cell growth in the body**

## Key Transaction Figures

**£167.7M** Upfront investment

**£41.7M** Following first lifileucel approval

# Targeting Potential Authorized Treatment Centers (ATCs)

30 Active ATCs at Approval; ~50 ATCs Expected 90 Days Post-PDUFA



## Targeting Considerations

- Patient volume
- NCCN status, KOLs
- Existing cell therapy / BMT
- Inpatient capacity
- Iovance clinical trial

## Drive Demand

- Top account prioritization
- Community referrals

1. Amtagvi.com (Last accessed February 28, 2024)


Abbreviations: ATC=Authorized Treatment Centers; NCCN=National Comprehensive Cancer Network; KOL=Key Opinion Leaders; BMT=Bone Marrow Transplant

# Market Access

Payers appreciate the high unmet need, lack of treatment options, and AMTAGVI clinical value

## Metastatic Melanoma Payer Mix<sup>1</sup>

All Treatment Settings and Lines of Therapy




## Anticipated Access

- Engagement with payers responsible for ~90% of covered lives
- Strong hospital reimbursement expected
  - Inpatient payment methodologies are established
  - Key payers expected to reimburse majority of provider costs
- Expect similar coverage to CAR-Ts

1. Metastatic Melanoma Insurance Claims Analysis, TIL-eligible patients treated in the ATC setting (1/1/2018–6/30/2021). Medicaid is 6% Medicaid Advantage and 1% Medicaid Fee-For-Service; For the 12% Medicare FFS lives, 11 PPS-exempt hospitals are reimbursed by Medicare FFS on a cost-basis (~4%), with the remaining Medicare FFS lives (~8%) reimbursed under DRG-018 payment methodology, NTAP/Outlier payments may add to the total Medicare reimbursement. Other segment includes cash, self-insured, VA, and other unidentifiable claims.  
Abbreviations: FFS=Fee-For-Service; ICD-10 PCS=International Classification of Diseases, 10<sup>th</sup> Revision, Procedure Coding System; NTAP = New Technology Add-on Payment



# Supporting Providers & Patients: IovanceCares™



Abbreviations: COI=Chain of Identity; COC=Chain of Custody

# AMTAGVI™ Expansion Plans in Advanced Melanoma

# Ex-U.S. Unmet Medical Need for Metastatic Melanoma Therapy

Expanding AMTAGVI™ launch ex-U.S. to double addressable patient population

## Preparing for EU MAA and Additional Ex-U.S. Submissions in 2024

**57k**

Annual deaths worldwide<sup>1</sup>

**15k**

Annual deaths in ex-U.S. target markets<sup>1</sup>

### Annual Deaths from Melanoma in Target Ex-U.S. Markets<sup>1</sup>

**3.2K** Germany **1.4K** Australia


**2.8K** UK **1.2K** Canada

**2.2K** Italy **1.1K** Spain

**2.1K** France **0.9K** Netherlands

### Melanoma Drug-Treated Population in 2021<sup>2</sup>

Unresectable / Metastatic (EU5)




1. World Health Organization International Agency for Research on Cancer (IARC). GLOBOCAN 2020

2. Clarivate DRG Disease Landscape (2021)

# TILVANCE-301 Global Phase 3 and Confirmatory Trial

Randomized, multicenter study with optional crossover to offer all patients potential to receive lifileucel (NCT05727904)







# Iovance TIL Clinical Highlights in Combination with Pembrolizumab in Metastatic Melanoma

**Lifileucel in combination with anti-PD-1/PD-L1 therapy in ICI-naïve patients (IOV-COM-202 Cohort 1A, N=12)<sup>1</sup>**

66.7%<sub>ORR</sub>

- 8 / 12 patients had a confirmed objective response per RECIST v1.1 (3 CRs & 5 PRs)
- 6 / 8 responders had ongoing response
- 5 responders had DOR >1 year
- FDA Fast Track Designation

1. As assessed by investigator using RECIST 1.1 (January 20, 2022 data cutoff)  
2. Each bar is presented for each patient starting from date of TIL infusion up to date of new anti-cancer therapy, end of assessment, death, or data cutoff date, whichever occurs earlier.  
Abbreviations: CR=complete response; ICI=immune checkpoint inhibitor; ORR=objective response rate; PR=partial response; SD=stable disease; pembro=pembrolizumab; RECIST=Response Evaluation Criteria in Solid Tumors



# TIL Therapy Pipeline

# Significant Market Potential in Solid Tumors and our Key Programs

91%

of all cancer cases  
are solid tumors<sup>1</sup>

1.8M

New cases of solid  
tumors in the U.S.<sup>1</sup>

Move into earlier line of therapy			
		U.S. Deaths <sup>1</sup>	Global Deaths <sup>2</sup>
Expand into other indications	Melanoma	8K	57K
	Lung & Bronchus	127K	1.8M
	Cervical	4K	342K
	Endometrial	13K	97K

1. National Cancer Institute Surveillance, Epidemiology and End Results (SEER) Program. 2023 Estimates. <https://seer.cancer.gov> accessed February 2024

2. World Health Organization International Agency for Research on Cancer (IARC). GLOBOCAN 2020

# Potential Market for Advanced Non-Small Cell Lung Cancer (NSCLC)

Addressing a Substantial Unmet Need in Metastatic NSCLC

## Iovance TIL clinical program:


- 6 cohorts across 3 trials
- Multiple treatment regimens
- Various populations and stages of disease

**127K** annual deaths in U.S.<sup>1</sup>

Leading cause of U.S. cancer deaths, accounting for ~1 in 5 cancer-related deaths<sup>2</sup>

9% 5-year survival rate<sup>2</sup> and real-world overall survival <6 months<sup>3</sup> in U.S.

NSCLC Drug-Treated Population in 2022  
Stage IV (US and EU5)<sup>4</sup>



1. National Cancer Institute Surveillance, Epidemiology and End Results (SEER) Program. 2023 Estimates. <https://seer.cancer.gov> accessed February 2024

2. American Cancer Society, Lung Cancer. <https://www.cancer.org/cancer/types/lung-cancer/about.html> accessed July 2023

3. National Cancer Database, NSCLC survival from >1 million patients assessed. Lou Y et al. Survival trends among non-small-cell lung cancer patients over a decade: impact of initial therapy at academic centers. Cancer Med. 2018.


4. Clarivate DRG Disease Landscape (2021)

Abbreviations: EU5=France, Germany, Italy, Spain and United Kingdom; 1L=first line therapy, 2L=second line therapy, 3L=third line therapy, 4L=fourth line therapy; mOS=median overall survival



# IOV-LUN-202 Trial Design

Phase 2 Multicenter Study of LN-145<sup>†</sup> in Patients Post-Anti-PD-1 NSCLC (NCT04614103)\*




\* U.S. FDA placed a partial clinical hold on the IOV-LUN-202 trial on December 22, 2023. Enrollment for new patients is paused. Patients previously treated continue to be monitored and followed. Patients who have already undergone tumor resection will continue to receive the LN-145 TIL treatment regimen with additional precautions and risk mitigations..

<sup>†</sup>Gen 2 TIL product <sup>††</sup> Cohort 3 patients unable to undergo surgical harvest, TIL grown from core biopsy

Abbreviations: Anti-PD-1, anti-programmed cell death inhibitor; IRC, independent review committee; NSCLC, non-small-cell lung cancer; ORR, objective response rate; TPS, tumor proportion score

# Preliminary Clinical Results for IOV-LUN-202 Cohorts 1 and 2

Objective Response Rate of 26.1% by RECIST 1.1, Regardless of PD-L1 Status



Data cut: July 6, 2023. 21 evaluable patients for response.  
Abbreviations: CR, complete response; NSCLC, non-small-cell lung cancer; PR, partial response; SD=stable disease; SOD, sum of diameters; TPS, tumor proportion score.

# Preliminary Clinical Results for IOV-LUN-202 Cohorts 1 and 2

All Patients Progressed on or After Anti-PD-1 Therapy and Chemotherapy


	Cohort 1 + 2 (n=23) <sup>2</sup>
Objective Response Rate, n (%) <sup>1</sup>	6 (26.1)
(95% CI)	(10.2, 48.4)
Best overall response, n (%)	
CR	1 (4.3)
PR	5 (21.7)
SD	13 (56.5)
PD	2 (8.7)
NE	2 (8.7)

TEAEs were consistent with the underlying disease and known AE profiles of NMA-LD and IL-2

1. Data cut: July 6, 2023. Responses were assessed by investigator.  
2. Patients who have progressed on or after chemotherapy and anti-PD-1 therapy for advanced (unresectable or metastatic) NSCLC without EGFR, ROS or ALK genomic mutations and had received at least one line of an FDA-approved targeted therapy if indicated by other actionable tumor mutations.  
Abbreviations: AE, adverse event; CI, confidence interval; CR, complete response; ICI, immune checkpoint inhibitor; NE, not evaluable; NMA-LD, non-myeloablative lymphodepletion; NSCLC, non-small-cell lung cancer; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease; TEAE, treatment-emergent AE.

# Preliminary Clinical Results for IOV-LUN-202 Cohorts 1 and 2


All Responses Remain Ongoing at Time of Data Cut



Data cut: July 6, 2023.  
A bar is presented for each patient starting from date of LN-145 infusion up to date of new anti-cancer therapy, end of assessment, death, or data cutoff date, whichever occurs earlier.  
Abbreviations: CR, complete response; DOR, duration of response; NSCLC, non-small-cell lung cancer; PR, partial response.

# Cohort 3A Summary

Proof-of-Concept for TIL in ICI-Naïve NSCLC Regardless of PD-L1 Status



## Clinical Activity at 18.2 Months of Follow Up<sup>1,2</sup>

- Activity across ICI naïve subgroups and TPS Scores
- 58.3% (7/12) ORR and 3 ongoing responses in NSCLC patients with EGFR<sup>WT</sup> disease
- Safety consistent with Iovance TIL combination studies
- Supports proposed registrational trial design in patients with EGFR<sup>WT</sup> disease in the frontline setting

Cohort 3A Results Support Adding TIL Therapy to Frontline Pembrolizumab + Chemotherapy Combination Regimens

1. Schoenfeld, et al. WCLC 2023


2. Data cut: June 26, 2023

Abbreviations: cy/flu, cytarabine/fluorouracil; EGFR, epidermal growth factor receptor; ICI, immune checkpoint inhibitor; IL-2, interleukin-2; NMA-LD, non-myeloablative lymphodepletion; TPS, tumor proportion score; WT, wild type



# Frontline NSCLC Registrational Trial: Design Supported by Cohort 3A Data

Adding TIL Therapy to Standard-of-Care Therapy



\* SOC Chemo-IO is 4-6 cycles of pembro + platinum-based chemotherapy doublet

1. KEYTRUDA USPI

2. Ghandi et al, NEJM 2018

Benchmarks	EGFR/ALK status	ORR	mDOR (mos)	mPFS (mos.)	Prior IO	Prior Chemo	PD-L1 (%)	SQ or NSQ
Keynote-189 <sup>1,2</sup>	WT	48%	11.2	8.8	No	No	All	NSQ
PD-L1 <1 Subgroup <sup>1,2</sup>	WT	32%			No	No	<1	NSQ
Keynote-407 <sup>1</sup>	N/A	58%	7.2	6.4	No	No	All	SQ

Abbreviations: EGFR, epidermal growth factor receptor; mDOR, median duration of response; NSCLC, non-small-cell lung cancer; NSQ, nonsquamous; platinum doublet, pemetrexed and cisplatin or carboplatin; PD-L1, programmed death ligand 1; PR, partial response; Pt, patient; SOC, standard of care; SQ, squamous; TPS, tumor proportion score; WT, wild-type

# Phase 1/2 Open-Label First-in-Human Study: IOV-GM1-201

Genetically Modified, PD-1 Inactivated TIL Therapy IOV-4001 in Previously Treated Metastatic Melanoma and NSCLC (NCT05361174)

## Patient Population

Adults with unresectable or metastatic melanoma or advanced NSCLC

N=53

**Cohort 1: Unresectable or metastatic melanoma**  
Post-anti-PD-1/L1, post-BRAF/MEK inhibitor in patients with BRAF mutations

**Cohort 2: Stage III or IV NSCLC**  
Post-anti-PD-1/L1 or post targeted therapy and either chemotherapy or anti-PD-1/L1

## Endpoints

- Phase 1: Safety
- Phase 2: Objective Response Rate (ORR) per RECIST v1.1 as assessed by the investigator
- Secondary endpoints include complete response (CR) rate, duration of response (DOR), disease control rate (DCR), progression free survival (PFS), overall survival (OS), safety and tolerability, feasibility

## Study Updates

- 3Q22: first patient treated

# Trailblazing Next-Generation TIL Programs



## Genetically modify TIL

Collectis gene-editing  
TALEN® collaboration<sup>1,2</sup>

PD-1 and other  
immune checkpoint  
targets (single and  
multiple knockouts)

Cytokine-tethered TILs



## Optimize TIL composition

PD-1+ selected TIL

CD39/69 double  
negative TILs<sup>3</sup>



## Next-generation processes

Gen 3 (16-day) process

Core biopsy



## Expand TIL into new regimens

IOV-3001 IL-2  
analog licensed  
from Novartis: IND  
enabling studies

1. Ritthipichai et al., ESMO 2020  
2. Natarajan, et al., AACR 2022  
3. Cubas et al., ESMO IO 2021

# Corporate Summary & Milestones

# Well-Capitalized in Pursuit of TIL Commercialization

February 22, 2024

(in millions)

**Cash, cash equivalents, investments, restricted cash**

**\$485.2<sup>1</sup>**

**Common shares outstanding**

**279.3**

**Preferred shares outstanding**

**2.9<sup>2</sup>**

**Stock options and restricted stock units outstanding**

**22.0**

**Cash runway is sufficient well into second half of 2025<sup>3</sup>**

1. Unaudited cash position which includes net proceeds of approximately \$197.1 million from a follow-on equity financing in February of 2024. Includes Restricted Cash of \$66.4 million.

2. Preferred shares are shown on an as-converted basis

3. Includes anticipated revenue from Amtagvi™ and Proleukin®



# Anticipated 2024 Milestones

## REGULATORY

- ☒ Obtain FDA approval for lifileucel in advanced melanoma (approved on Feb. 16, 2024)
- ☐ Submit EMA regulatory dossier (1H24)
- ☐ Submit additional ex-US dossiers (2H24)
- ☐ Meet with FDA to discuss NSCLC registrational path/frontline study

## PIPELINE

- ☐ Report clinical and pre-clinical data
- ☐ Resume enrollment in IOV-LUN-202
- ☐ Initiate Phase 2 trial in endometrial cancer
- ☐ Continue to enroll patients in clinical trials for advanced melanoma, NSCLC and gynecological cancers
- ☐ Advance new products toward clinic, including additional genetically-modified TIL therapies

## MANUFACTURING

- ☐ Fulfill patient demand for commercial launch and clinical trials
- ☐ Further expand capacity to meet US and ex-US demand

## COMMERCIAL

- ☐ Execute commercial launch (1Q24)
- ☐ On-board 50 ATCs within 90 days of PDUFA date

# Corporate Highlights

Pioneering a Transformational Approach to Cure Cancer

## Large Market Opportunity in High Unmet Need Cancers

- Initial focus in post-ICI solid tumors
- Expansion into combinations, earlier lines of therapy and genetic modifications
- Key late-stage trials in melanoma, NSCLC and cervical cancer
- First-in-human trial of genetically modified PD-1 inactivated TIL

## First FDA Approved T Cell Therapy for a Solid Tumor Cancer

- FDA accelerated approval for AMTAGVI™ in advanced melanoma
- TILVANCE-301 Phase 3 confirmatory trial in frontline advanced melanoma (FTD)
- Defined registration strategy in NSCLC and cervical cancer (BTD)

## Efficient and Scalable Proprietary Manufacturing Facility

- Iovance Cell Therapy Center (iCTC) in-house manufacturing
- Additional capacity with contract manufacturers
- Rapid 22-day Gen 2 manufacturing
- >700 patients treated with Iovance proprietary process



## Fully Integrated for Commercial Success

- Experienced cross-functional cell therapy team
- TIL service-line capabilities established with leading U.S. cancer centers
- IovanceCares™ proprietary platform



Thank You

ADVANCING IMMUNO-ONCOLOGY